Sanofi: EC Approves Sarclisa SC For Multiple Myeloma, First EU Therapy Via On-Body Injector

(RTTNews) - The European Commission has approved Sarclisa (isatuximab) subcutaneous (SC) in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all existing indications for Sarclisa intravenous (IV) formulation, Sanofi SA (SN